explore
Previous article:
The cancer drug shortage isn’t new — and neither are the solutions
Next article: Tome Biosciences co
Next article: Tome Biosciences co
hotspot
focus
-
Listen: More tumult at BIO & coercive care for sickle cell patients
2025-09-27 08:47 -
At flashy new research hub, AstraZeneca lays out ambitious growth goals
2025-09-27 08:43 -
Tome Biosciences co
2025-09-27 08:15 -
Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead
2025-09-27 08:13 -
Readout Newsletter: Amylyx, Aurinia, and IQVIA
2025-09-27 07:21 -
Biogen joins immunology wave with $1.15 billion acquisition of HI
2025-09-27 07:03